Mycophenolate sodium controlled release - Novartis

Drug Profile

Mycophenolate sodium controlled release - Novartis

Alternative Names: EC-MPS; ERL 080; ERL 080A; Mycophenolic acid - Novartis; Myfortic

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; University of Pittsburgh
  • Class Benzofurans; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase II Liver transplant rejection
  • No development reported Heart transplant rejection; Lupus nephritis

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for mycophenolate sodium in USA and Europe (Novartis 20-F filed in 2017)
  • 09 Jan 2014 First generic equivalent available in USA for Renal transplant rejection
  • 18 Nov 2009 Novartis completes a phase II trial in Lupus nephritis in Hungary, France, Great Britain, Greece, Denmark, Italy and Spain (EudraCT2006-002107-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top